Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Aug 16.

Published in final edited form as: Circulation. 2022 Jun 21;146(7):535–547. doi: 10.1161/CIRCULATIONAHA.122.058575

Figure 2. — Cost-effectiveness acceptability curve showing the probability of a strategy being cost-effective over a range of willingness-to-pay (WTP) thresholds for (A) the entire CABANA cohort (N=2204), and (B) the heart failure subgroup with NYHA class ≥II symptoms (N=778). The red and blue lines represent the base case and sensitivity analysis with attenuation in quality of life after 5 years, respectively.

Figure 2. — Cost-effectiveness acceptability curve showing the probability of a strategy being cost-effective over a range of willingness-to-pay (WTP) thresholds for (A) the entire CABANA cohort (N=2204), and (B) the heart failure subgroup with NYHA class ≥II symptoms (N=778). The red and blue lines represent the base case and sensitivity analysis with attenuation in quality of life after 5 years, respectively.